NCI begins rewrite of cancer center grant guidelines; will allow clinical investigator support. Goal is to implement P30-P50 working group recommendations, simplify guidelines, Karen Antman tells advisory board.
NCI considers allowing some centers to opt out of site visits.
Board of Scientific Advisors discussion: Are peer reviewers correctly interpreting the guidelines?
Also in this 8-page issue: John Mendelsohn selected for BMS award. National Coalition for Cancer Survivorship and The Wellness Community begin advocacy initiative.
Business & Regulatory Report March edition (8 pages) included.
Trending Stories
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns
